Centers for Disease Control and Prevention (CDC), Division of Global HIV and TB, Atlanta, GA.
United States Agency for International Development (USAID), Office of HIV/AIDS, Washington, DC.
J Acquir Immune Defic Syndr. 2023 May 1;93(1):15-24. doi: 10.1097/QAI.0000000000003166.
Adolescents have poorer outcomes across the HIV cascade compared with adults. We aimed to assess progress in HIV case finding, antiretroviral treatment (ART), viral load coverage (VLC), and viral load suppression (VLS) among adolescents enrolled in the US President's Emergency Plan for AIDS Relief (PEPFAR)-supported programs over a 3-year period that included the beginning of the COVID-19 pandemic.
We analyzed PEPFAR program data in 28 countries/regions for adolescents aged 10-19 years between year 1 (October 2017to September 2018), year 2 (October 2018 to September 2019), and year 3 (October 2019 to September 2020). We calculated the number and percent change for HIV tests, HIV-positive tests, and total number on ART. Calculated indicators included positivity, percent of positives newly initiated on ART (ART linkage), VLC (percent of ART patients on ART for ≥6 months with a documented viral load result within the past 12 months), and VLS (percent of viral load tests with <1000 copies/mL).
Between years 1 and 3, the number of HIV tests conducted decreased by 44.2%, with a 29.1% decrease in the number of positive tests. Positivity increased from 1.3%-1.6%. The number of adolescents receiving ART increased by 10.4%. In addition, ART linkage increased (77.8%-86.7%) as did VLC (69.4%-79.4%) and VLS (72.8%-81.5%).
Our findings demonstrate PEPFAR's success in increasing the adolescent treatment cohort. We identified ongoing gaps in adolescent case finding, linkage, VLC, and VLS that could be addressed with a strategic mix of testing strategies, optimal ART regimens, and adolescent-focused service delivery models.
与成年人相比,青少年在艾滋病病毒各个环节的结局较差。本研究旨在评估在开始出现 COVID-19 大流行的 3 年期间,接受美国艾滋病紧急救援计划(PEPFAR)支持的项目的青少年中,在艾滋病毒发现、抗逆转录病毒治疗(ART)、病毒载量覆盖率(VLC)和病毒载量抑制(VLS)方面的进展情况。
我们分析了 28 个国家/地区 10-19 岁青少年的数据,包括 2017 年 10 月至 2018 年 9 月的第 1 年、2018 年 10 月至 2019 年 9 月的第 2 年和 2019 年 10 月至 2020 年 9 月的第 3 年。我们计算了 HIV 检测、HIV 阳性检测和开始接受 ART 的总人数的数量和百分比变化。计算指标包括阳性率、新开始接受 ART 的阳性率(ART 连接)、VLC(在过去 12 个月内有记录的病毒载量结果的接受 ART 治疗≥6 个月的 ART 患者的百分比)和 VLS(病毒载量检测中<1000 拷贝/ml 的百分比)。
在第 1 年至第 3 年期间,进行的 HIV 检测数量减少了 44.2%,阳性检测数量减少了 29.1%。阳性率从 1.3%-1.6%上升。接受 ART 的青少年人数增加了 10.4%。此外,ART 连接率(77.8%-86.7%)、VLC(69.4%-79.4%)和 VLS(72.8%-81.5%)均有所增加。
我们的研究结果表明,PEPFAR 成功地增加了青少年治疗群体。我们发现,在青少年病例发现、连接、VLC 和 VLS 方面仍存在差距,可通过采用混合检测策略、优化的 ART 方案和以青少年为中心的服务提供模式来解决这些差距。